⌘K

09:00:00·84d

PRRelease

Alpha Tau Issues Letter to Shareholders: Five Concurrent Trials in the U.S. with Multiple Significant Value-Driving Milestones Ahead

DRTS· Alpha Tau Medical Ltd.

Health Care

Original source

Companies

DRTS
Alpha Tau Medical Ltd.
Health Care

Recent analyst ratings

Mar 4UpdatePiper Sandler$5.00
Dec 15UpdateCitigroup$8.00
Apr 24UpdateH.C. Wainwright$9.00
Apr 14UpdateCantor Fitzgerald$20.00
Apr 8UpdatePiper Sandler$19.00
Apr 4UpdateCitigroup$21.00

Related

SEC17h
SEC Form 6-K filed by Alpha Tau Medical Ltd.
PR17h
Alpha Tau Announces FDA Approval of IDE Supplement to Expand Alpha DaRT® IMPACT Trial to Patients with Pancreatic Cancer Receiving Gemcitabine with Abraxane® (Nab-Paclitaxel)
PR17h
Alpha Tau Successfully Treats First Pancreatic Cancer Patient in Europe with Alpha DaRT® in French Multicenter ACAPELLA Clinical Trial
SEC23d
SEC Form 6-K filed by Alpha Tau Medical Ltd.
PR23d
Alpha Tau Announces First-Ever Oral Presentation of Alpha DaRT® Pancreatic Cancer Data at Digestive Disease Week (DDW) 2026
INSIDER36d
SEC Form 3 filed by new insider Avruch Michael
INSIDER36d
SEC Form 3 filed by new insider Kidron Nadav
INSIDER36d
SEC Form 3 filed by new insider Sofer Uzi